Navigation Links
Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
Date:2/28/2013

of $31.5 million from the sale of our equity interest in Optimer Biotechnology, Inc. (OBI).

At December 31, 2012, Optimer held cash, cash equivalents and short-term investments of $124.0 million.  This includes proceeds from the sale of our equity interest in OBI, which was completed in the fourth quarter.Optimer had 47.8 million shares outstanding on December 31, 2012.

"Healthcare policy is shifting to new ways to control healthcare spending, particularly in hospitals.  Many of our recent research initiatives, such as analyzing the cost burden of Clostridium difficile infection, are designed to assist hospitals to better understand the disease burden on their patients and institutions," said Dr. McKinnell.

As of December 31, 2012:

  • Inventory levels at wholesalers remain within the range of 14 to 28 days of demand
  • Approximately 2,750 hospitals had ordered DIFICID
  • About 83% of hospitals covered by Optimer have reordered DIFICID
  • Approximately 1,000 hospitals are estimated to have placed DIFICID on formulary
  • As a result of the management changes announced yesterday and processes and procedures in connection therewith, we have determined that the filing of our Form 10-K will be delayed.Conference Call and Webcast 
    The Company will host a conference call and webcast to discuss its fourth quarter and fiscal year 2012 financial results and provide a corporate update today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

    The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers.  Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Optimer Pharmaceuticals Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
    2. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
    3. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
    4. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
    5. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
    6. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
    7. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
    8. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
    9. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
    10. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
    11. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
    (Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
    (Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
    Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
    ... 2012 /PRNewswire-Asia-FirstCall/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... report on Form 20-F for the year ended ... and Exchange Commission (the "SEC"). The annual report ...
    ... Mindray Medical International Limited (NYSE: MR ), ... worldwide, announced today that it has filed with the ... 20-F that included audited financial statements for the year ... Annual Report on Form 20-F is available on Mindray,s ...
    Cached Medicine Technology:ShangPharma Corporation Files 2011 Annual Report on Form 20-F 2Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
    (Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
    (Date:12/26/2014)... 2014 Pentec Health, Inc. number fourteen ... of Pennsylvania for 2014. The awards program, created in ... its kind in the country. The program is a ... of Community and Economic Development, the Pennsylvania State Council ... Central Penn Business Journal. , Charlie Wilson, ...
    (Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
    (Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
    (Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
    Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
    ... Association (BMA) has claimed that children who grow up ... mental health problems //. ,A recent report ... suffer from several mental health-related problems, such as unstable ... ,Those brought up in care or as asylum-seekers are ...
    ... District Health Boards and Primary Health Organisations, (PHOs), which faced ... both parties reaching an agreement on the extension of ... who are GP patients, aged between 45 - 64 years, ... GPs have long been at loggerheads over the conditions, ...
    ... After signing contracts with the District Health Boards (DHBs), striking junior ... // , ,The doctor's union - Resident ... for about six hours on Monday and planned to meet on ... doctors took part in the strike, which lasted for 5 days. ...
    ... MRSA (Meticillin Resistant Staphylococcus Aureus) is a bacteria resistant ... who suffer //from weakened immune systems, especially in hospitals ... of poor hygiene. ,Countries like the Netherlands, Sweden, ... stable for many years are now facing an increase ...
    ... authorities report – 'In Zambia, people in the tourist resort ... after finding dead chickens at the owners backyards'. // ... said 'No confirmed evidences were found after thorough investigation of ... died is not been cleared yet but residents who cooked ...
    ... in the near future for those suffering with the deadly disease ... Mary Harney said that he would speak with the government for ... people infected with these diseases while administering blood and blood products. ... patients especially women. , These people suffer from the ...
    Cached Medicine News:Health News:Super-bug MRSA Getting Fitter And Out of Control 2
    Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
    Severe revision options for the knee and hip...
    Severe revision options for the knee and hip...
    The Precedent establishes a new generation of revision hip stems....
    Medicine Products: